Shots:

• The EC has approved the Viatris merger (a merger b/w Upjohn and Mylan) under EU merger regulations but the decision is conditional on the divestment of Mylan's certain generic therapies
• EC ensures that the merger does not harm competition and preserves the competitive access to certain genericized therapies for national health services and the citizens of EU. The EC has investigated the vertical relationships b/w the companies concerning API- out-licensing the supply of genericized therapies
• Mylan and Upjohn overlap in multiple therapeutic areas such as CV- Genito-urinary- musculoskeletal- CNS and sensory organ treatments- but no competition concerns arise for most of the products. The concern was found for 36 molecules in certain EU countries- requiring Mylan to offload those therapies

Click here ­to­ read full press release/ article | Ref: European Commission  | Image: Pharmabiz

Related News: Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic